CD20-negative Epstein–Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia-Reference-Cited by-同舟云学术

CD20-negative Epstein–Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

Published:2011-05-11 Issue:6 Volume:93 Page:779-781
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Muramatsu Hideki,Takahashi Yoshiyuki,Shimoyama Yoshie,Doisaki Sayoko,Nishio Nobuhiro,Ito Yoshinori,Hama Asahito,Shimada Akira,Yagasaki Hiroshi,Ito Masafumi,Kojima Seiji

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-011-0870-3.pdf

Reference8 articles.

1. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–92.

2. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.

3. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885–93.

4. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.

5. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502–5.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation;Annals of Hematology;2023-12-29

2. Management of PTLD After HSCT;Post-Transplant Lymphoproliferative Disorders;2021

3. Antitumor activity of cyclin‐dependent kinase inhibitor alsterpaullone in Epstein‐Barr virus‐associated lymphoproliferative disorders;Cancer Science;2019-12-11

4. Managing post-transplant lymphoproliferative disorder;Expert Opinion on Orphan Drugs;2016-11-24

5. Targeting Epstein-Barr virus–transformed B lymphoblastoid cells using antibodies with T-cell receptor–like specificities;Blood;2016-09-08